Search results
Results from the WOW.Com Content Network
No one likes being given the wrong information. Investors reacted in dismay and sent Fibrogen (FGEN) shares deep into the red following the company's embarrassing announcement. The biotech company ...
Last month, the FDA approved Biogen’s Alezheimer’s disease drug Aducanumab, in a controversial decision that went against the advisory committee’s recommendation. When looking at the case of ...
The stock of FibroGen (NAS:FGEN, 30-year Financials) is estimated to be possible value trap, according to GuruFocus Value calculation.
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F ...
One thing we could say about the analysts on FibroGen, Inc. ( NASDAQ:FGEN ) - they aren't optimistic, having just made... News Flash: 10 Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Earnings Are ...
Roxadustat is reported to increase VEGF, a signal protein that can activate tumor growth [8] and also is considered to cause pulmonary hypertension. [9] In phase 3 trial conducted at 29 sites in China, roxadustat treatment was found to cause hyperkalemia, i.e., increase in serum potassium, and metabolic acidosis in patients.
You are free: to share – to copy, distribute and transmit the work; to remix – to adapt the work; Under the following conditions: attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made.
(Reuters) -FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca in the United States and certain other territories after the companies agreed to ...